ATE254287T1 - Verfahren zum nachweis beta-amyloid-reduzierenden-agenzien - Google Patents

Verfahren zum nachweis beta-amyloid-reduzierenden-agenzien

Info

Publication number
ATE254287T1
ATE254287T1 AT98911801T AT98911801T ATE254287T1 AT E254287 T1 ATE254287 T1 AT E254287T1 AT 98911801 T AT98911801 T AT 98911801T AT 98911801 T AT98911801 T AT 98911801T AT E254287 T1 ATE254287 T1 AT E254287T1
Authority
AT
Austria
Prior art keywords
amyloid
reducing agents
beta
detecting beta
present
Prior art date
Application number
AT98911801T
Other languages
English (en)
Inventor
Barbara Cordell
Linda Slanec Higgins
Original Assignee
Scios Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios Inc filed Critical Scios Inc
Application granted granted Critical
Publication of ATE254287T1 publication Critical patent/ATE254287T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98911801T 1997-03-21 1998-03-19 Verfahren zum nachweis beta-amyloid-reduzierenden-agenzien ATE254287T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/821,876 US6221670B1 (en) 1997-03-21 1997-03-21 Methods to identify β-amyloid reducing agents
PCT/US1998/005363 WO1998043094A1 (en) 1997-03-21 1998-03-19 METHODS TO IDENTIFY β-AMYLOID REDUCING AGENTS

Publications (1)

Publication Number Publication Date
ATE254287T1 true ATE254287T1 (de) 2003-11-15

Family

ID=25234504

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98911801T ATE254287T1 (de) 1997-03-21 1998-03-19 Verfahren zum nachweis beta-amyloid-reduzierenden-agenzien

Country Status (9)

Country Link
US (1) US6221670B1 (de)
EP (1) EP0970379B1 (de)
JP (1) JP2002508834A (de)
AT (1) ATE254287T1 (de)
AU (1) AU6567198A (de)
CA (1) CA2284261A1 (de)
DE (1) DE69819696T2 (de)
ES (1) ES2212277T3 (de)
WO (1) WO1998043094A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528071A (ja) * 2000-03-23 2003-09-24 エラン ファーマスーティカルズ インコーポレイテッド アルツハイマー病治療用組成物および方法
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
GB0010565D0 (en) * 2000-05-02 2000-06-21 Medical Res Council Assay for acetylcholinesterase inhibitors
JP2004502665A (ja) * 2000-06-30 2004-01-29 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病を治療する化合物
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
WO2003002122A1 (en) * 2001-06-27 2003-01-09 Elan Pharmaceuticals, Inc. Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
US20070213407A1 (en) * 2001-06-29 2007-09-13 Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc Compounds to treat Alzheimer's disease
US6846641B2 (en) * 2002-04-23 2005-01-25 Agy Therapeutics, Inc. In vitro ischemia model
EP1633786A4 (de) * 2002-10-09 2007-07-25 Rinat Neuroscience Corp Verfahren zur behandlung der alzheimer-krankheit mit antikörpern gegen amyloid-beta-peptid und zusammensetzungen daraus
GEP20115195B (en) * 2004-07-30 2011-04-11 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and use thereof
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
CL2007002908A1 (es) 2007-10-09 2008-05-30 Univ Concepcion Procedimiento electroquimico in vitro para evaluar capacidad neurotoxica de estructuras, principios activos y/o compuestos de interes en celulas vivas y que comprende medir y cuantificar los parametros electricos en membranas expuestas a dichos agreg
US20130046093A1 (en) * 2011-08-18 2013-02-21 Korea Institute Of Science And Technology Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same
US9638548B2 (en) 2012-05-07 2017-05-02 Infineon Technologies Ag Output switching systems and methods for magnetic field sensors
US10102992B2 (en) 2014-02-25 2018-10-16 Infineon Technologies Ag Switching apparatus, switching system and switching method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production

Also Published As

Publication number Publication date
US6221670B1 (en) 2001-04-24
ES2212277T3 (es) 2004-07-16
DE69819696D1 (de) 2003-12-18
JP2002508834A (ja) 2002-03-19
DE69819696T2 (de) 2004-09-16
EP0970379B1 (de) 2003-11-12
AU6567198A (en) 1998-10-20
WO1998043094A1 (en) 1998-10-01
CA2284261A1 (en) 1998-10-01
EP0970379A1 (de) 2000-01-12

Similar Documents

Publication Publication Date Title
DE69819696D1 (de) Verfahren zum nachweis beta-amyloid-reduzierenden-agenzien
DE69510342D1 (de) Verfahren zum nachweis der permeabilität eines gegenstandes für sauerstoff
DE69513248D1 (de) Zusammensetzung, Verfahren und System zum Nachweis von Leukocyten, Esterasen oder Proteasen in einer Testprobe
DE59405710D1 (de) Mittel zur rauchsimulation für streulichtrauchmelder, verfahren zum abgleich von deren rauchempfindlichkeit und verwendung des mittels
DE59601159D1 (de) Verfahren zum gegenseitigen ausrichten von körpern und lagemesssonde hierfür
DE60031548D1 (de) Verfahren zum simultanen nachweis von beiden gliedern eines bindungspaares
DE69128344D1 (de) Vorrichtung und verfahren für elektrochemische messungen
DE69827066D1 (de) Verfahren und Vorrichtung zum Kompensieren von Mehrkanalechos
DE59912155D1 (de) Verfahren und vorrichtung zum statischen oder dynamischen ermitteln von sollwerten für bremskräfte oder bremsmomente
DE3776302D1 (de) Verfahren zur feststellung von gasen unter anwendung von chemisorption und physisorption.
DE69019088D1 (de) Verfahren und Apparat zur Erneuerung einer Elektrode eines Biosensors.
DE69327775D1 (de) Verfahren zur Vorbehandlung für Blutanalyse
DE69417900D1 (de) Vorrichtung und Verfahren zum schnellen und hochempfindlichen Erkennen und Zählen von Mikroorganismen mittels Fluoreszenz
ATE278803T1 (de) Verfahren zur überwachung der proteasomeinhibitorarzneimitteleffekte
DE3575621D1 (de) Verfahren und anordnung zum kennzeichnen und erkennen von gegenstaenden.
DE3674453D1 (de) Verfahren und vorrichtung zur zerstoerungsfreien pruefung ferromagnetischer koerper.
DE59707425D1 (de) Verfahren und teststreifen zur bestimmung eines analyten
DE69413042D1 (de) Verfahren und vorrichtung zum feststellen der verschiebung eines gegenstandes
DE69020355D1 (de) Verfahren zur befestigung eines elastischen streifens.
DE69521622D1 (de) System und verfahren zur sprachverarbeitung mittels multipuls-analyse
DE69504949T3 (de) Verwendung eines Antagonisten der Substanz P zur Behandlung von Hautrötungen neurogen Ursprungs
DE69208108D1 (de) Verfahren und Vorrichtung zur Prüfung von Gasleckage
DE69320457D1 (de) Verfahren und anordnung für bioaffinitätsassays
DE69837575D1 (de) Vorrichtung und Verfahren zur Inkubation von Teststreifen
DE59812865D1 (de) Verfahren zur Reduzierung von Störungen bei der Übertragung eines elektrischen Nachrichtensignals

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties